ETFs & MarketsBasicBiogen Secures Subcutaneous Leqembi Approval: What It Means for Your ETF
Biogen has received regulatory approval for a subcutaneous version of its Alzheimer's drug Leqembi for the initiation dose. This clinical milestone could significantly alter the delivery landscape for neurodegenerative treatments and impact major biotech-focused exchange-traded funds.
Published 1 hour ago
Read more →